The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. Grimm, S. E., Strong, M., Brennan, A., & Wailoo, A. J. PharmacoEconomics, 35(12):1287–1296, December, 2017. Paper doi abstract bibtex Background Recent changes to the regulatory landscape of pharmaceuticals may sometimes require reimbursement authorities to issue guidance on technologies that have a less mature evidence base. Decision makers need to be aware of risks associated with such health technology assessment (HTA) decisions and the potential to manage this risk through managed entry agreements (MEAs).
@article{grimm_hta_2017,
title = {The {HTA} {Risk} {Analysis} {Chart}: {Visualising} the {Need} for and {Potential} {Value} of {Managed} {Entry} {Agreements} in {Health} {Technology} {Assessment}},
volume = {35},
issn = {1170-7690, 1179-2027},
shorttitle = {The {HTA} {Risk} {Analysis} {Chart}},
url = {http://link.springer.com/10.1007/s40273-017-0562-9},
doi = {10.1007/s40273-017-0562-9},
abstract = {Background Recent changes to the regulatory landscape of pharmaceuticals may sometimes require reimbursement authorities to issue guidance on technologies that have a less mature evidence base. Decision makers need to be aware of risks associated with such health technology assessment (HTA) decisions and the potential to manage this risk through managed entry agreements (MEAs).},
language = {en},
number = {12},
urldate = {2020-05-12},
journal = {PharmacoEconomics},
author = {Grimm, Sabine Elisabeth and Strong, Mark and Brennan, Alan and Wailoo, Allan J.},
month = dec,
year = {2017},
pages = {1287--1296},
file = {Grimm et al. - 2017 - The HTA Risk Analysis Chart Visualising the Need .pdf:/Users/neil.hawkins/Zotero/storage/4869J42V/Grimm et al. - 2017 - The HTA Risk Analysis Chart Visualising the Need .pdf:application/pdf},
}
Downloads: 0
{"_id":"iqmTR8rtGofkkuDC5","bibbaseid":"grimm-strong-brennan-wailoo-thehtariskanalysischartvisualisingtheneedforandpotentialvalueofmanagedentryagreementsinhealthtechnologyassessment-2017","author_short":["Grimm, S. E.","Strong, M.","Brennan, A.","Wailoo, A. J."],"bibdata":{"bibtype":"article","type":"article","title":"The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment","volume":"35","issn":"1170-7690, 1179-2027","shorttitle":"The HTA Risk Analysis Chart","url":"http://link.springer.com/10.1007/s40273-017-0562-9","doi":"10.1007/s40273-017-0562-9","abstract":"Background Recent changes to the regulatory landscape of pharmaceuticals may sometimes require reimbursement authorities to issue guidance on technologies that have a less mature evidence base. Decision makers need to be aware of risks associated with such health technology assessment (HTA) decisions and the potential to manage this risk through managed entry agreements (MEAs).","language":"en","number":"12","urldate":"2020-05-12","journal":"PharmacoEconomics","author":[{"propositions":[],"lastnames":["Grimm"],"firstnames":["Sabine","Elisabeth"],"suffixes":[]},{"propositions":[],"lastnames":["Strong"],"firstnames":["Mark"],"suffixes":[]},{"propositions":[],"lastnames":["Brennan"],"firstnames":["Alan"],"suffixes":[]},{"propositions":[],"lastnames":["Wailoo"],"firstnames":["Allan","J."],"suffixes":[]}],"month":"December","year":"2017","pages":"1287–1296","file":"Grimm et al. - 2017 - The HTA Risk Analysis Chart Visualising the Need .pdf:/Users/neil.hawkins/Zotero/storage/4869J42V/Grimm et al. - 2017 - The HTA Risk Analysis Chart Visualising the Need .pdf:application/pdf","bibtex":"@article{grimm_hta_2017,\n\ttitle = {The {HTA} {Risk} {Analysis} {Chart}: {Visualising} the {Need} for and {Potential} {Value} of {Managed} {Entry} {Agreements} in {Health} {Technology} {Assessment}},\n\tvolume = {35},\n\tissn = {1170-7690, 1179-2027},\n\tshorttitle = {The {HTA} {Risk} {Analysis} {Chart}},\n\turl = {http://link.springer.com/10.1007/s40273-017-0562-9},\n\tdoi = {10.1007/s40273-017-0562-9},\n\tabstract = {Background Recent changes to the regulatory landscape of pharmaceuticals may sometimes require reimbursement authorities to issue guidance on technologies that have a less mature evidence base. Decision makers need to be aware of risks associated with such health technology assessment (HTA) decisions and the potential to manage this risk through managed entry agreements (MEAs).},\n\tlanguage = {en},\n\tnumber = {12},\n\turldate = {2020-05-12},\n\tjournal = {PharmacoEconomics},\n\tauthor = {Grimm, Sabine Elisabeth and Strong, Mark and Brennan, Alan and Wailoo, Allan J.},\n\tmonth = dec,\n\tyear = {2017},\n\tpages = {1287--1296},\n\tfile = {Grimm et al. - 2017 - The HTA Risk Analysis Chart Visualising the Need .pdf:/Users/neil.hawkins/Zotero/storage/4869J42V/Grimm et al. - 2017 - The HTA Risk Analysis Chart Visualising the Need .pdf:application/pdf},\n}\n\n","author_short":["Grimm, S. E.","Strong, M.","Brennan, A.","Wailoo, A. J."],"bibbaseid":"grimm-strong-brennan-wailoo-thehtariskanalysischartvisualisingtheneedforandpotentialvalueofmanagedentryagreementsinhealthtechnologyassessment-2017","role":"author","urls":{"Paper":"http://link.springer.com/10.1007/s40273-017-0562-9"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/f/FfNE7kWA6pCvwcJZF/Exported Items.bib","dataSources":["ZaHtWavQhcwZqKLNF","iRRNaRs6FkffgErta","v8uQmZsBpiqycmskv","XJsLMZaQ4gqK57JBt"],"keywords":[],"search_terms":["hta","risk","analysis","chart","visualising","need","potential","value","managed","entry","agreements","health","technology","assessment","grimm","strong","brennan","wailoo"],"title":"The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment","year":2017}